ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Tools
Markets
Discover
Subscribe Login/Register Profile Icon
S&P ASX 200
7,194.90
(
0.3%
)
S&P ASX All Technology
2,523.80
(
-0.39%
)
Brent Oil
75.965
(
0.0%
)
US Dollar vs AUD
1.51906
(
0.0%
)
Bitcoin
43,897.53
(
-0.65%
)
Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Aprea Therapeutics Inc (APRE)

  7. Aprea Therapeutics Inc (APRE) News

APRE Aprea Therapeutics Inc

3.685
0.01 (0.27%)
09 Dec 2023 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Stock Type
Aprea Therapeutics Inc APRE NASDAQ Common Stock
  Price Change Price Change % Share Price Last Trade
Upgrade Icon
0.01 0.27% 3.685 08:03:21
Open Price Low Price High Price Close Price Previous Close
3.60 3.5817 3.8099 3.685 3.675
more quote information »

Recent News

Date Time Source Heading
10/11/202308:20EDGAR2Form S-8 - Securities to be offered to employees in employee..
10/11/202308:15EDGAR2Form 8-K - Current report
10/11/202308:10EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
17/10/202308:29EDGAR2Form 8-K - Current report
13/10/202322:31EDGAR2Form 8-K - Current report
11/9/202322:30EDGAR2Form 8-K - Current report
25/8/202311:52EDGAR2Form 4 - Statement of changes in beneficial ownership of..
25/8/202311:50EDGAR2Form 4 - Statement of changes in beneficial ownership of..
25/8/202311:48EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24/8/202322:00EDGAR2Form 8-K - Current report
10/8/202321:39EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
10/8/202321:36EDGAR2Form 8-K - Current report
11/7/202321:40EDGAR2Form ARS - Annual Report to Security Holders
11/7/202321:30EDGAR2Form DEF 14A - Other definitive proxy statements
06/7/202306:01EDGAR2Form 8-K - Current report
14/6/202322:00GLOBEAprea Therapeutics to Present at Maxim Virtual Healthcare..
30/5/202322:30GLOBEAprea Therapeutics to Present at BIO International..
16/5/202306:05GLOBEAprea Therapeutics Reports First Quarter 2023 Financial..
08/5/202322:00GLOBEAprea Therapeutics Appoints Gabriela Gruia, M.D. to Board of..
31/3/202307:05GLOBEAprea Therapeutics Reports Fourth Quarter and Full Year 2022..
16/3/202323:00GLOBEAprea Therapeutics Announces Presentation of Preclinical..
08/3/202300:00GLOBEAprea Therapeutics to Present at Oppenheimer’s 33rd Annual..
02/3/202308:05GLOBEAprea Therapeutics Regains Compliance with Nasdaq Minimum..
28/2/202308:05GLOBEAprea Therapeutics Announces Closing of $5.5 Million..
23/2/202312:41GLOBEAprea Therapeutics Announces Pricing of $5.5 Million..
23/2/202308:05GLOBEAprea Therapeutics Announces Proposed Public Offering of..
16/2/202300:00GLOBEAprea Therapeutics Announces Phase II SBIR Award from the..
13/2/202323:00GLOBEAprea Therapeutics Announces One-for-Twenty Reverse Stock..
31/1/202300:00GLOBEAprea Therapeutics Appoints John Hamill as Chief Financial..
20/1/202300:00GLOBEAprea Therapeutics to Participate in 6th Annual DNA Damage..
12/1/202301:25APSBiotech Bid Up Following First Patient Dosage
12/1/202300:00GLOBEAprea Therapeutics Announces Dosing of First Patient in..

Your Recent History

NASDAQ
APRE
Aprea Therapeutics
Delayed Upgrade Clock

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: 1-888-992-3836 | help@advfn.com